Question | Discussion | References | CME Credit

Case 4: References

  1. Clements-Nolle K, Marx R, Guzman R, Katz M. HIV Prevalence, Risk Behaviors, Health Care Use, and Mental Health Status of Transgender Persons: Implications for Public Health Intervention. Am J Pub Health. 2001;91:915-21.
    [The following link will open in a new window. PubMed Abstract]
  2. Simon PA, Reback CJ, Bemis CC. HIV prevalence and incidence among male-to-female transsexuals receiving HIV prevention services in Los Angeles County [correspondence]. AIDS. 2000;14:2953–5.
    [The following link will open in a new window. PubMed Abstract]
  3. Kellogg TA, Clements-Nolle K, Dilley J, Katz MH, McFarland W. Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco. J Acquir Immune Defic Syndr. 2001;28:380-4.
    [The following link will open in a new window. PubMed Abstract]
  4. Hessol NA, Lifson AR, O'Malley PM, Doll LS, Jaffe HW, Rutherford GW. Prevalence, incidence, and progression of human immunodeficiency virus infection in homosexual and bisexual men in hepatitis B vaccine trials, 1978–1988. Am J Epidemiol. 1989;130:1167–75.
    [The following link will open in a new window. PubMed Abstract]
  5. Elifson KW, Boles J, Posey E, Sweat M, Darrow W, Elsea W. Male transvestite prostitutes and HIV risk. Am J Public Health. 1993;83:260-2.
    [The following link will open in a new window. PubMed Abstract]
  6. Nemoto T, Luke D, Mamo L, Ching A, Patria J. HIV risk behaviors among male-to-female transgenders in comparison with homosexual or bisexual males and heterosexual females. AIDS Care. 1999;11:297-312.
    [The following link will open in a new window. PubMed Abstract]
  7. Nemoto T, Operario D, Keatley J, Vellegas D. Social context of HIV risk behaviours among male-to-female transgenders of colour. AIDS Care. 2004;16:724-35.
    [The following link will open in a new window. PubMed Abstract]
  8. The Harry Benjamin International Gender Dysphoria Association. HBIGDA standards of care for gender identity disorders. 6th Version. February 2001. Available at:
    [The following link will open in a new window. Harry Benjamin International Gender Dysphoria Association - Accessed April 1, 2006]
  9. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol. 2003; 59:409-18.
    [The following link will open in a new window. PubMed Abstract]
  10. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-73.
    [The following link will open in a new window. PubMed Abstract]
  11. Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989;38:869-73.
    [The following link will open in a new window. PubMed Abstract]
  12. van Kesteren P, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47:337-42.
    [The following link will open in a new window. PubMed Abstract]
  13. Tom Waddell Health Center. Protocols for hormone reassignment of gender.
    [The following link will open in a new window. PDF Document - Accessed April 1, 2006]
  14. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88:5723-9.
    [The following link will open in a new window. PubMed Abstract]
  15. Greenman Y. The endocrine care of transsexual people. J Clin Endocrinol Metab. 2004;89:1014.
    [The following link will open in a new window. PubMed Abstract]
  16. Symmers WS. Carcinoma of the breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J. 1968;2:82–5.
    [The following link will open in a new window. PubMed Abstract]
  17. Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-Karim FW. Breast cancer in a male-to-female transsexual. A case report. JAMA. 1988; 259:2278-80.
    [The following link will open in a new window. PubMed Abstract]
  18. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82:341.
    [The following link will open in a new window. PubMed Abstract]
  19. Markland C. Transexual surgery. Obstet Gynecol Annu. 1975;4:309-30.
    [The following link will open in a new window. PubMed Abstract]
  20. Thurston AV. Carcinoma of the prostate in a transsexual. Br J Urol. 1994;73:217.
    [The following link will open in a new window. PubMed Abstract]
  21. van Haarst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM. Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol. 1998;81:776.
    [The following link will open in a new window. PubMed Abstract]
  22. Amprenavir (Agenerase) prescribing information. GlaxoSmithKline.
    [The following link will open in a new window. PDF Document - Accessed April 1, 2006]
  23. Bartlett JG, Lane HC, and the Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 6, 2005. Available at:
    [The following link will open in a new window. AIDSinfo - Accessed April 1, 2006]

[Back to Case 4 Question | Back to Discussion]

CME Credit | Back to Top